Literature DB >> 27322113

The delineation of intraprostatic boost regions for radiotherapy using multimodality imaging.

Angela U Pathmanathan1, Emma J Alexander2, Robert A Huddart1, Alison C Tree2.   

Abstract

Dose escalation to the prostate improves tumor control but at the expense of increased rectal toxicity. Modern imaging can be used to detect the most common site of recurrence, the intraprostatic lesion (IPL), which has led to the concept of focusing dose escalation to the IPL in order to improve the therapeutic ratio. Imaging must be able to detect lesions with adequate sensitivity and specificity to accurately delineate the IPL. This information must be carefully integrated into the radiotherapy planning process to ensure the dose is targeted to the IPL. This review will consider the role and challenges of multiparametric MRI and PET computed tomography in delineating a tumor boost to be delivered by external beam radiotherapy.

Entities:  

Keywords:  MRI; PET-CT; boost; dose escalation; intraprostatic lesion; prostate cancer

Mesh:

Year:  2016        PMID: 27322113     DOI: 10.2217/fon-2016-0129

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  3 in total

Review 1.  MR-guided radiotherapy for prostate cancer: state of the art and future perspectives.

Authors:  Kobika Sritharan; Alison Tree
Journal:  Br J Radiol       Date:  2022-02-09       Impact factor: 3.039

2.  Evaluation of Dose-Painting in the Dominant Intraprostatic Lesions by Radiobiological Parameters using 68Ga- PSMA PET/CT.

Authors:  Khadijeh Bamneshin; Seied Rabi Mahdavi; Ahmad Bitarafan-Rajabi; Parham Geramifar; Payman Hejazi; Fereshteh Koosha; Majid Jadidi
Journal:  J Biomed Phys Eng       Date:  2022-08-01

3.  MRI-guided adaptive radiotherapy for prostate cancer: When do we need to account for intra-fraction motion?

Authors:  R Lawes; H Barnes; T Herbert; A Mitchell; S Nill; U Oelfke; A Pathmanathan; G Adair Smith; K Sritharan; A Tree; H A McNair; A Dunlop
Journal:  Clin Transl Radiat Oncol       Date:  2022-09-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.